TrialJournal of hematology & oncology2016
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
56 papers cite it
this paperpooled ittrialcites it